Guangdong Association Of Clinical Trials
Clinical trials sponsored by Guangdong Association Of Clinical Trials, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a blood test tell which lung cancer patients can skip chemo? Results expected Dec 2026 (estimated)
- Smart blood tests may personalize lung cancer care after targeted therapy Results expected Dec 2026 (estimated)
- Single-Drug immunotherapy shows promise for advanced lung cancer Results expected May 2027 (estimated)
- New hope for KRAS-driven lung cancer: drug duo targets tough mutation Results expected Sep 2027 (estimated)
-
New combo therapy shows promise for lung cancer brain metastases
Disease control CompletedThis study tested whether adding the immunotherapy drug camrelizumab to standard chemotherapy and radiation helps people with advanced lung cancer whose disease has spread to the brain. The trial included 60 patients who had not received chemotherapy before. Researchers measured …
Phase 3 • Sponsor: Guangdong Association of Clinical Trials • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Lung cancer drug cocktail shows promise in delaying tumor growth
Disease control CompletedThis Phase 3 study tested whether adding bevacizumab (Avastin) to erlotinib (Tarceva) works better than erlotinib alone for Chinese patients with advanced non-small cell lung cancer (NSCLC) that has specific EGFR mutations. Over 300 patients were randomly assigned to one of the t…
Phase 3 • Sponsor: Guangdong Association of Clinical Trials • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC